Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy

Leukemia

Volumn 31, Issue 4, 2017, Pages 872-881

  Uy, G L ^a   Duncavage, E J ^a   Chang, G S ^a   Jacoby, M A ^a   Miller, C A ^a   Shao, J ^a   Heath, S ^a   Elliott, K ^a   Reineck, T ^a   Fulton, R S ^a   Fronick, C C ^a   O'Laughlin, M ^a   Ganel, L ^a   Abboud, C N ^a   Cashen, A F ^a   Dipersio, J F ^a   Wilson, R K ^a   Link, D C ^a   Welch, J S ^a   Ley, T J ^a   Graubert, T A ^b   Westervelt, P ^a   Walter, M J ^a   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COHESIN; DECITABINE; PANOBINOSTAT; PROTEIN P53; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR;

ACUTE MYELOID LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW; CANCER RECURRENCE; CLONAL EVOLUTION; CYTOGENETICS; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE MUTATION; GENE THERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NAUSEA; NEXT GENERATION SEQUENCING; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; TUMOR VOLUME; CLINICAL TRIAL; DRUG EFFECTS; EXOME; GENETIC EPIGENESIS; GENETICS; HIGH THROUGHPUT SEQUENCING; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; REMISSION; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CLONAL EVOLUTION; EPIGENESIS, GENETIC; EXOME; FEMALE; GENES, P53; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HISTONE DEACETYLASE INHIBITORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; POLYMORPHISM, SINGLE NUCLEOTIDE; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84995747477     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.282     Document Type: Article

References (36)

1. Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2009; 28: 556-561
2. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-2440
3. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794-1803
4. Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with 430% blasts. Blood 2015; 126: 291-299
5. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562-569
6. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232
7. Silverman LR, Fenaux P, Mufti GJ, Santini V, Hellstrom-Lindberg E, Gattermann N et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 2011; 117: 2697-2702
8. Gore SD, Fenaux P, Santini V, Bennett JM, Silverman LR, Seymour JF et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica 2013; 98: 1067-1072
9. Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012; 366: 1090-1098
10. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642-4649
11. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419-425
12. Walter MJ, Shen D, Shao J, Ding L, White BS, Kandoth C et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 2013; 27: 1275-1282
13. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150: 264-278
14. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481: 506-510
15. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 2009; 280: 233-241
16. Welch J, Petti A, Miller C, Fronick C, O'Laughlin M, Fulton R et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. NEJM (in press)
17. Klco JM, Miller CA, Griffith M, Petti A, Spencer DH, Ketkar-Kulkarni S et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA 2015; 314: 811-822
18. Research TCGA. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-2074
19. San-Miguel JF, Richardson PG, Gunther A, Sezer O, Siegel D, Blade J et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol 2013; 31: 3696-3703
20. Jackson-Grusby L, Laird PW, Magge SN, Moeller BJ, Jaenisch R. Mutagenicity of 5-aza-2'-deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc Natl Acad Sci USA 1997; 94: 4681-4685
21. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012; 30: 2670-2677
22. Lubbert M, Suciu S, Baila L, Ruter BH, Platzbecker U, Giagounidis A et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011; 29: 1987-1996
23. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; 28: 241-247
24. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122: 3616-3627
25. Metzeler KH, Walker A, Geyer S, Garzon R, Klisovic RB, Bloomfield CD et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia 2012; 26: 1106-1107
26. Itzykson R, Kosmider O, Cluzeau T, Mansat-Mas V, Dreyfus F, Beyne-Rauzy O et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011; 25: 1147-1152
27. Bejar R, Lord A, Stevenson K, Bar-Natan M, Perez-Ladaga A, Zaneveld J et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood 2014; 124: 2705-2712
28. Traina F, Visconte V, Elson P, Tabarroki A, Jankowska AM, Hasrouni E et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia 2014; 28: 78-87
29. Craddock C, Quek L, Goardon N, Freeman S, Siddique S, Raghavan M et al. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia 2013; 27: 1028-1036
30. Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C, Tamari R et al. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood 2012; 120: 2076-2086
31. Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014; 20: 1472-1478
32. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG et al. Agerelated clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371: 2488-2498
33. Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371: 2477-2487
34. McKerrell T, Park N, Moreno T, Grove CS, Ponstingl H, Stephens J et al. Leukemiaassociated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Rep 2015; 10: 1239-1245
35. Merlevede J, Droin N, Qin T, Meldi K, Yoshida K, Morabito M et al. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nat Commun 2016; 7: 10767
36. Boumber Y, Kantarjian H, Jorgensen J, Wen S, Faderl S, Castoro R et al. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia 2012; 26: 2428-2431